Prime Medicine, Inc. financials

PRME CIK 0001894562

Source: EDGAR filings · Built 2026-06-02T03:52:31Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2022FY 2022
Free Cash Flow -167.09M -130.16M -174.14M -147.92M -38.23M -6.18M
EBITDA -201.03M -196.34M -200.14M -114.32M -83.91M -889.00K
Working Capital 143.84M 173.93M 86.55M 269.90M 212.60M
Net Debt 53.40M -141.68M -27.94M -158.88M -175.01M
Operating Margin -4498.06% -6787.36% -17.89%
Net Margin -4342.44% -6566.61% -65.45%
Return on Equity (ROE) -166.41% -127.90% -148.89% -38.52% 105.84% -145.85%
Return on Assets (ROA) -58.69% -65.84% -102.21% -33.81% -54.78%
Current Ratio 4.84× 5.58× 2.53× 11.10× 4.67×
Debt-to-Equity 0.96× 0.27× 0.10× 0.09× -0.07×
Cash Conversion Ratio 0.81× 0.63× 0.83× 1.08× 0.21× 1.63×
Accruals Ratio -0.11× -0.25× -0.17× 0.03× -0.43×
SBC % of Revenue 631.87% 873.89% 7.50%
CapEx Coverage -35.88× -16.84× -18.96× -8.19× -8.21× -8.68×
Free Cash Flow Per Share $-1.12 $-1.10 $-1.91 $-4.36 $-2.95 $-2.34

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2022FY 2022
P/S 135.23× 128.39×
P/B 5.18× 2.50× 6.48× 5.71×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2022FY 2022
Revenue from Contract with Customer, Excluding Assessed Tax 4.63M 2.98M 0 0 0 5.21M
Research and Development Expense 160.64M 155.29M 147.91M 86.72M 70.55M 2.98M
Operating Expenses 212.98M 205.45M 204.79M 116.54M 84.47M 6.14M
Operating Income (Loss) -208.35M -202.47M -204.79M -116.54M -84.47M -932.00K
Income Tax Expense (Benefit) 0 0 -279.00K -948.00K -486.00K 1.87M
Net Income (Loss) Attributable to Parent -201.14M -195.88M -198.13M -121.82M -165.37M -3.41M
Earnings Per Share, Basic $-1.35 $-1.65 $-2.18 $-4.19 $-14.19 $-1.91
Weighted Average Number of Shares Outstanding, Basic 148.76M 118.60M 90.97M 33.89M 12.97M 2.64M
Earnings Per Share, Diluted $-1.35 $-1.65 $-2.18 $-4.19 $-14.19 $-1.91
Weighted Average Number of Shares Outstanding, Diluted 148.76M 118.60M 90.97M 33.89M 12.97M 2.64M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2022FY 2022
Cash and Cash Equivalents, at Carrying Value 63.03M 182.48M 41.57M 187.62M 185.42M 36.98M
Assets, Current 181.29M 211.89M 142.98M 296.62M 270.58M
Assets 342.73M 297.51M 193.85M 360.31M 301.86M
Liabilities, Current 37.45M 37.96M 56.42M 26.71M 57.98M
Liabilities 221.87M 144.36M 60.78M 44.04M 62.30M
Stockholders' Equity Attributable to Parent 120.87M 153.15M 133.07M 316.27M -156.24M 2.34M
Common Stock, Shares, Outstanding 180.51M 131.16M 97.38M 97.21M 32.41M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2022FY 2022
Net Cash Provided by (Used in) Operating Activities -162.56M -122.86M -165.41M -131.83M -34.08M -5.54M
Payments to Acquire Property, Plant, and Equipment 4.53M 7.29M 8.72M 16.09M 4.15M 639.00K
Net Cash Provided by (Used in) Investing Activities -108.76M 68.46M 18.71M -47.10M -73.63M -1.06M
Net Cash Provided by (Used in) Financing Activities 151.51M 195.88M 655.00K 181.49M 269.28M 34.93M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (PRME CIK 0001894562), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

DTCX

Datacentrex, Inc.

NEU

NEWMARKET CORPORATION

VRSK

Verisk Analytics, Inc.